ÂÜÀòÂÒÂ×

Andy Billinton is currently the Chief Scientific Officer at Harness Therapeutics, previously holding the same position at Transine Therapeutics. Prior to their current roles, Andy has held various senior scientific positions at companies such as NodThera Limited, AstraZeneca, Transpharmation Ltd., and GlaxoSmithKline. Andy has a strong background in neuroscience and pain drug discovery, with a focus on leading research teams and projects from idea generation through to Phase 2 clinical trials. Andy's academic background includes a PhD in Neuroscience from the University of Birmingham and a BSc in Pharmacology from the University of Bristol.